Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekAJMC ↗
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS…
The WeekBioPharma Dive ↗
Gedatolisib could "establish a new standard of care" for PIK3CA-mutated breast cancer, an investigator said, b…
The WeekFiercePharma ↗
Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease an…
The WeekFierceBiotech ↗
Praxis Precision Medicines' epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to su…
The WeekBriefing
Obefazimod delivered industry-leading remission rates in ulcerative colitis, but new cancer cases wiped out th…
The WeekDrug Channels ↗
By Adam J. Fein, Ph.D. and Greis Kapexhiu It's time for Drug Channels Institute's latest exclusive analysis of…
The WeekDrug Channels ↗
By Adam J. Fein, Ph.D. and Greis Kapexhiu It's time for Drug Channels Institute's latest exclusive analysis of…
The WeekDrug Channels ↗
By Adam J. Fein, Ph.D. and Greis Kapexhiu It's time for Drug Channels Institute's latest exclusive analysis of…
The WeekBioPharma Dive ↗
At the year's biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scient…
The WeekSTAT News ↗
Growing legislative scrutiny across multiple states targets the corporate structure underlying most direct-to-…
The WeekAJMC ↗
Results Show Giving Prophylactic Tocilizumab Reduces CRS in Outpatient Delivery of Teclistamab, Talquetamab…
The WeekPharmaVoice ↗
With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio diseas…
The WeekFiercePharma ↗
Merck & Co.'s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already …
The WeekFierceBiotech ↗
Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-s…
The WeekBriefing
CEO Mark Goldsmith says the company will soon seek approval for its pancreatic cancer drug daraxonrasib and ha…
The WeekBioPharma Dive ↗
Orphan drugs remain commercially durable, strategically relevant and supported by a strong pipeline…
The WeekSTAT News ↗
The arbitration process has protected patients but generated financial windfalls for some clinicians.…
The WeekFiercePharma ↗
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
The WeekFierceBiotech ↗
Although the first-in-class PD-1xVEGF bispecific didn't disappoint on its overall survival headline message, d…
The WeekBriefing
AARP found top U.S. brand-name drugs climbed 81% in list price since launch while prices abroad fell 13%, hint…
The WeekSTAT News ↗
ASCO Day 3: A huge advance for pancreatic cancer, a let down for Akeso and Summit, and a new approach to immun…
The WeekAJMC ↗
Dual-Target ADC Shows 15-Month Progression-Free Survival in Prostate Cancer: Tanya Dorff, MD…
The WeekAJMC ↗
Phase 3 SUNMO Data Show Mosun-Pola Cuts Progression Risk Over R-GemOx in Large B-Cell Lymphoma: Elizabeth Budd…
The WeekBioPharma Dive ↗
Highly anticipated data presented at ASCO confirmed what's been heralded as a medical breakthrough against a h…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.